Immunic (NASDAQ:IMUX) Posts Earnings Results, Misses Expectations By $0.02 EPS

Immunic (NASDAQ:IMUX) posted its earnings results on Thursday. The company reported ($0.12) EPS for the quarter, missing the consensus estimate of ($0.10) by ($0.02), Zacks reports.

Immunic Price Performance

IMUX stock traded up $0.07 during midday trading on Friday, reaching $1.02. The company had a trading volume of 3,762,695 shares, compared to its average volume of 5,634,886. Immunic has a 1-year low of $0.51 and a 1-year high of $1.35. The stock has a 50 day moving average price of $0.70 and a 200-day moving average price of $0.76. The company has a market capitalization of $133.07 million, a price-to-earnings ratio of -1.46 and a beta of 1.58.

Hedge Funds Weigh In On Immunic

Several hedge funds have recently bought and sold shares of the company. Qube Research & Technologies Ltd bought a new stake in shares of Immunic during the 3rd quarter worth approximately $29,000. Two Sigma Investments LP acquired a new position in Immunic during the third quarter valued at approximately $52,000. Virtu Financial LLC acquired a new stake in shares of Immunic in the 3rd quarter valued at $99,000. XTX Topco Ltd bought a new position in shares of Immunic in the 4th quarter valued at $120,000. Finally, Jane Street Group LLC increased its stake in shares of Immunic by 46.8% in the 4th quarter. Jane Street Group LLC now owns 286,677 shares of the company’s stock valued at $153,000 after purchasing an additional 91,346 shares during the last quarter. 51.82% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several analysts recently issued reports on IMUX shares. Weiss Ratings restated a “sell (e+)” rating on shares of Immunic in a research note on Monday, December 29th. Roth Mkm began coverage on Immunic in a report on Friday, November 7th. They set a “buy” rating and a $3.00 target price for the company. D. Boral Capital decreased their price target on shares of Immunic from $8.00 to $4.00 and set a “buy” rating on the stock in a research note on Friday, February 13th. Chardan Capital raised shares of Immunic to a “strong-buy” rating in a research report on Wednesday, November 19th. Finally, Brookline Capital Acquisition upgraded shares of Immunic to a “strong-buy” rating in a research note on Tuesday, February 3rd. Three equities research analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $6.60.

About Immunic

Immunic, Inc is a clinical-stage biopharmaceutical company focused on developing novel oral therapies to treat chronic inflammatory and autoimmune diseases as well as certain cancers. The company’s research strategy centers on small-molecule immunology, aiming to offer targeted treatments with improved safety and tolerability profiles. By modulating key signaling pathways within the immune system, Immunic seeks to address underlying disease mechanisms and achieve durable therapeutic benefits for patients.

Immunic’s lead product candidate, vidofludimus calcium (IMU-838), is an oral selective dihydroorotate dehydrogenase (DHODH) inhibitor in Phase 2 clinical development for conditions including ulcerative colitis, Crohn’s disease and relapsing multiple sclerosis.